CN1044235C - 异噁唑基磺酰胺衍生物及其在制备内皮素拮抗剂中的用途 - Google Patents

异噁唑基磺酰胺衍生物及其在制备内皮素拮抗剂中的用途 Download PDF

Info

Publication number
CN1044235C
CN1044235C CN93103447A CN93103447A CN1044235C CN 1044235 C CN1044235 C CN 1044235C CN 93103447 A CN93103447 A CN 93103447A CN 93103447 A CN93103447 A CN 93103447A CN 1044235 C CN1044235 C CN 1044235C
Authority
CN
China
Prior art keywords
isoxazolyl
dimethyl
amino
naphthalene sulfonylamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93103447A
Other languages
English (en)
Chinese (zh)
Other versions
CN1079468A (zh
Inventor
P·D·施坦恩
J·T·亨特
N·穆卢格桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of CN1079468A publication Critical patent/CN1079468A/zh
Application granted granted Critical
Publication of CN1044235C publication Critical patent/CN1044235C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Glass Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN93103447A 1992-02-24 1993-02-24 异噁唑基磺酰胺衍生物及其在制备内皮素拮抗剂中的用途 Expired - Fee Related CN1044235C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84049692A 1992-02-24 1992-02-24
US840,496 1992-02-24

Publications (2)

Publication Number Publication Date
CN1079468A CN1079468A (zh) 1993-12-15
CN1044235C true CN1044235C (zh) 1999-07-21

Family

ID=25282528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93103447A Expired - Fee Related CN1044235C (zh) 1992-02-24 1993-02-24 异噁唑基磺酰胺衍生物及其在制备内皮素拮抗剂中的用途

Country Status (26)

Country Link
EP (1) EP0558258B1 (enExample)
JP (1) JP3273818B2 (enExample)
KR (1) KR100257134B1 (enExample)
CN (1) CN1044235C (enExample)
AT (1) ATE152713T1 (enExample)
AU (1) AU651922B2 (enExample)
CA (1) CA2089184A1 (enExample)
CY (1) CY2045B1 (enExample)
DE (1) DE69310414T2 (enExample)
DK (1) DK0558258T3 (enExample)
EG (1) EG20143A (enExample)
ES (1) ES2103061T3 (enExample)
FI (1) FI930774A7 (enExample)
GR (1) GR3024203T3 (enExample)
HK (1) HK121597A (enExample)
HU (1) HU219455B (enExample)
IL (1) IL104748A (enExample)
MX (1) MX9300842A (enExample)
MY (1) MY109004A (enExample)
NO (1) NO303012B1 (enExample)
NZ (1) NZ245905A (enExample)
PH (1) PH30795A (enExample)
PL (1) PL172035B1 (enExample)
RU (1) RU2116301C1 (enExample)
TW (1) TW224462B (enExample)
ZA (1) ZA93780B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
EP0626174A3 (en) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
ES2081251B1 (es) * 1993-08-04 1996-10-16 Squibb & Sons Inc Antagonistas de endotelina, a base de sulfonamida.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
JPH09504302A (ja) * 1993-11-01 1997-04-28 日本チバガイギー株式会社 エンドセリン・レセプター・アンタゴニスト
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
EP1048657A1 (en) * 1995-04-04 2000-11-02 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
TW402597B (en) * 1996-02-20 2000-08-21 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
JP3783411B2 (ja) 1997-08-15 2006-06-07 富士ゼロックス株式会社 表面発光型半導体レーザ
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
IL150311A0 (en) 1999-12-31 2002-12-01 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP4293734B2 (ja) * 2001-01-17 2009-07-08 三菱電機株式会社 電動式パワーステアリング制御装置
US7547716B2 (en) 2001-06-08 2009-06-16 Institute Of Medicinal Molecular Design, Inc. Sulfonamide derivatives
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
DE10256186A1 (de) * 2002-12-02 2004-06-09 Bayer Ag Cyclopenta(c)isoxazol-3-amine als Materialschutzmittel
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
MX2007004862A (es) * 2004-10-29 2007-05-09 Astrazeneca Ab Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
AU2006316867A1 (en) 2005-11-22 2007-05-31 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
JP4518066B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 ジアルコキシニトリル誘導体及びその製法
JP4518065B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 新規ジアルコキシアミドオキシム誘導体及びその製法
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
TW200951114A (en) 2008-05-20 2009-12-16 Astrazeneca Ab Phenyl or pyridinyl substituted indazoles derivatives
CN101818056B (zh) * 2010-05-27 2013-07-31 中南大学 一类丹磺酰类分子探针及其合成方法和应用
AR089838A1 (es) * 2012-01-31 2014-09-17 Eisai R&D Man Co Ltd Derivados de sitaxetan
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300488A (en) * 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
GB1473433A (enExample) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888455A (en) * 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
US3422095A (en) * 1966-11-04 1969-01-14 Hoffmann La Roche N**1-and/or n**4-(lower alkoxyacetyl) sulfanilamides
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
TW270116B (enExample) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300488A (en) * 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
GB1473433A (enExample) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi

Also Published As

Publication number Publication date
EG20143A (en) 1997-07-31
FI930774L (fi) 1993-08-25
HU219455B (hu) 2001-04-28
ZA93780B (en) 1993-09-08
FI930774A7 (fi) 1993-08-25
ES2103061T3 (es) 1997-08-16
JP3273818B2 (ja) 2002-04-15
FI930774A0 (fi) 1993-02-22
PH30795A (en) 1997-10-17
NO930633L (no) 1993-08-25
MX9300842A (es) 1993-08-01
CY2045B1 (en) 1998-04-30
HU9300491D0 (en) 1993-05-28
KR930017881A (ko) 1993-09-20
PL297820A1 (en) 1993-09-06
IL104748A (en) 1996-10-16
NZ245905A (en) 1995-07-26
DE69310414D1 (de) 1997-06-12
EP0558258A1 (en) 1993-09-01
JPH069585A (ja) 1994-01-18
IL104748A0 (en) 1993-06-10
TW224462B (enExample) 1994-06-01
DE69310414T2 (de) 1997-12-11
GR3024203T3 (en) 1997-10-31
RU2116301C1 (ru) 1998-07-27
KR100257134B1 (ko) 2000-05-15
NO303012B1 (no) 1998-05-18
AU651922B2 (en) 1994-08-04
HK121597A (en) 1997-09-12
CA2089184A1 (en) 1993-08-25
AU3319293A (en) 1993-08-26
EP0558258B1 (en) 1997-05-07
DK0558258T3 (da) 1997-05-26
HUT65762A (en) 1994-07-28
PL172035B1 (pl) 1997-07-31
MY109004A (en) 1996-11-30
NO930633D0 (no) 1993-02-23
ATE152713T1 (de) 1997-05-15
CN1079468A (zh) 1993-12-15

Similar Documents

Publication Publication Date Title
CN1044235C (zh) 异噁唑基磺酰胺衍生物及其在制备内皮素拮抗剂中的用途
CN1109026C (zh) 带有侧链的紫杉烷类化合物
CN1057295C (zh) 磺酰胺类内皮素拮抗剂及其用途
CN1060172C (zh) 取代的联苯磺酰胺类内皮素拮抗剂
CN1304390C (zh) 新颖的γ—分泌酶抑制剂
CN1093124C (zh) 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物
CN1036920C (zh) 含杂环碳酸衍生物
CN100338073C (zh) 取代的苯乙酸
CN1022487C (zh) 制备新的药物化合物
CN1280574A (zh) 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
CN1071917A (zh) 用作人类免疫缺陷病毒逆转录酶拮抗剂的喹唑啉衍生物
CN1053607A (zh) 用于治疗aids的人体免疫缺乏病毒蛋白酶的抑制剂
CN1145587A (zh) 蛋白酶抑制剂
CN1059210C (zh) 制备6－杂环－4－氨基－1,3,4,5－四氢苯并[cd]吲哚及其可作药用的酸加成盐的方法
CN1444570A (zh) 非甾体抗炎药
CN1128262A (zh) 取代的联苯噁唑磺酰胺
CN1107158A (zh) 多取代的2-氨基-噻唑衍生物
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1764648A (zh) 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
CN1105358A (zh) N-取代氨杂双环庚烷衍生物，其制备方法以及用途
CN1056685A (zh) 吲哚衍生物及其制备方法
CN1108657A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1127492C (zh) 抗风湿剂
CN1211183A (zh) 联苯基异噁唑磺酰胺的制备方法
CN1056690A (zh) 吡咯并哒嗪化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee